Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab + umbralisib versus obinutuzumab + chlorambucil in chronic lymphocytic leukemia
2015-005758-36Phase 3Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ublituximab, umbralisib, obinutuzumab and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Progression-free survival. Started Sep 2016; status: terminated.
02
Drugs
ublituximabumbralisibobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-005758-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005758-36.